Therapeutic Asset Ratings
309 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
H-gamma1 heavy chain Homo sapiens (1-447) [VH (Homo sapiens IGHV4-59*01 (99.0%) -(IGHD) -IGHJ3*02 (93.3%) T125>I (114), CDR-IMGT [8.7.11] (26-33.51-57.96-106)) (1-117) -Homo sapiens IGHG1*01, G1m17,1 CH1 K120, CH3 D12, L14, 9-G1v21 CH2 Y15.1, T16, E18 (CH1 K120 (214) (118-215), hinge 1-15 (216-230), CH2 M15.1>Y (252), S16>T (254), T18>E (256) (231-340), CH3 D12 (356), L14 (358) (341-445), CHS (446-447)) (118-447)], (220-214')-disulfide with L-kappa light chain Homo sapiens (1'-214') [V-KAPPA (Homo sapiens IGKV3-11*01 (96.8%) -IGKJ4*01 (100%), CDR-IMGT [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo sapiens IGKC*01 (100%) Km3 A45.1, V101 (CKAPPA A45.1 (153'), V101 (191')) (108'-214')]; dimer (226-226'':229-229'')-bisdisulfide, produced in a cell line derived from Chinese hamster ovary (CHO) cells, glycoform alfa
Melanoma
Kineta Inc.
P1/2
CC
(44)
L-Valine, S-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenonyl-2-(aminomethyl)-4-thiazolecarbonyl-2-methylalanyl-, (5?2)-lactone, benzenesulfonate (1:1)
Melanoma
OnKure, Inc.
P1/2
CC
(44)
Tucidinostat
Melanoma
Peking University Cancer Hospital & Institute
P1/2
CC
(44)
Vedolizumab
Melanoma
M.D. Anderson Cancer Center
P1/2
CC
(44)
Adoptive Therapy With Autologous Mc2 Tcr T Cells
Melanoma
Erasmus Medical Center
P1/2
CC
(41)
Alintegimod
Melanoma
7 Hills Pharma, LLC
P1/2
CC
(41)
Amt-116 Car-T Cells
Melanoma
Beijing Immunochina Medical Science & Technology Co., Ltd.
P1/2
CC
(41)
Amt-253 Car-T Cells
Melanoma
Beijing Immunochina Medical Science & Technology Co., Ltd.
P1/2
CC
(41)
Amxt1501
Melanoma
Aminex Therapeutics, Inc.
P1/2
CC
(41)
Anti-Hcd70 Car Transduced Pbl
Melanoma
National Cancer Institute (NCI)
P1/2
CC
(41)
APG 115
Melanoma
Ascentage Pharma Group Inc.
P1/2
CC
(41)
azd6750
Melanoma
AstraZeneca
P1/2
CC
(41)
Bgb-A445
Melanoma
BeiGene
P1/2
CC
(41)
bi-1808
Melanoma
BioInvent International AB
P1/2
CC
(41)
bi 853520
Melanoma
Hangzhou Hanx Biopharmaceuticals, Ltd.
P1/2
CC
(41)
Bms-936558-01
Melanoma
Bristol-Myers Squibb
P1/2
CC
(41)
Cjrb-101
Melanoma
CJ Bioscience, Inc.
P1/2
CC
(41)
Dapansutrile
Melanoma
April Salama, M.D.
P1/2
CC
(41)
DLL3 CAR-T cells
Melanoma
Shenzhen Geno-Immune Medical Institute
P1/2
CC
(41)
Eflornithine
Melanoma
Aminex Therapeutics, Inc.
P1/2
CC
(41)
Fluzoparib
Melanoma
Jun Guo
P1/2
CC
(41)
Fosdesdenosine Sipalabenamide
Melanoma
NuCana plc
P1/2
CC
(41)
Gamma1 heavy chain humanized (1-450) [VH (Homo sapiens IGHV4-31*01 (89.9%) -(IGHD) -IGHJ4*01 (92.9%), CDR-IMGT [9.7.13] (26-34.52-58.97-109)) (1-120) -Homo sapiens IGHG1*01 (100%), G1m17,1 CH1 K120, D12, L14 (CH1 K120 (217) (121-218), hinge 1-15 (219-233), CH2 (234-343), CH3 D12 (359), L14 (361) (344-448), CHS (449-450)) (121-450)], (223-214')-disulfide with kappa light chain humanized (1'-214') [V-KAPPA (Homo sapiens IGKV1-12*01 (85.3%)-IGKJ2*01 (100%), CDR-IMGT [6.3.9] (27-32.50-52.89-97)) (1'-107') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (229-229'':232-232'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, derived from the cell line CHO-K1,glycoform alfa
Melanoma
Cancer Research UK
P1/2
CC
(41)
gen1042
Melanoma
Genmab
P1/2
CC
(41)
hx009
Melanoma
Hangzhou Hanx Biopharmaceuticals, Ltd.
P1/2
CC
(41)
Showing 151 to 175 of 309 assets
Previous
Page 7 of 13
Next
